<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918840</url>
  </required_header>
  <id_info>
    <org_study_id>PHPC-02</org_study_id>
    <secondary_id>2008-003765-11</secondary_id>
    <nct_id>NCT00918840</nct_id>
  </id_info>
  <brief_title>Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)</brief_title>
  <acronym>PHPC-02</acronym>
  <official_title>Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy Followed by Analytical Treatment Interruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genetic Immunity</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViroStatics srl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genetic Immunity</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether
      therapeutic immunization during highly active antiretroviral therapy (HAART) induces
      elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in
      HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load
      set point following analytical treatment interruption (ATI). Subjects will be randomized to
      receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects
      per cohort) every four weeks for three applications while receiving maximally suppressive
      HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 subjects on maximally suppressive HAART were randomized to receive three doses of either
      DermaVir or Placebo immunotherapy.

      Subjects receive three DermaVir/Placebo treatments over eight weeks (Weeks 0, 4 and 8) while
      receiving HAART. HAART is discontinued for a 20 week ATI.

      Resumption of HAART during ATI is subjects experience:

        -  A confirmed CD4+ cell decrease by &gt; 50%

        -  A confirmed CD4+ cell decrease to less than 350 counts/mL

        -  A confirmed VL increase &gt; 300,000 copies

        -  Emergence of CDC AIDS related event(s)

        -  Signs or symptoms of clinically significant immunosuppression

        -  The subject or the subject's clinician wishes to restart HAART

        -  The subject becomes pregnant
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-specific memory T cells measured as PHPC count</measure>
    <time_frame>9 week</time_frame>
    <description>DermaVir-induced PHPC count compared to Placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA</measure>
    <time_frame>weeks 16 and 20</time_frame>
    <description>HIV-1 RNA set-point after analytical treatment interruption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ and CD8+ T cell counts</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>DermaVir + HAART</arm_group_label>
    <description>Dosage: 0.4 mg DNA
Dosage form: 3.2 mL DNA/PEIm nanomedicine
Administration with 4 DermaPrep patches
Frequency: every 4 weeks
Duration: 8 weeks (3 DermaVir treatments)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + HAART</arm_group_label>
    <description>Dosage form: 3.2 mL Placebo
Administration with 4 DermaPrep patches
Frequency: every four weeks
Duration: 8 weeks (3 Placebo treatments)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DermaVir</intervention_name>
    <description>DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells</description>
    <arm_group_label>DermaVir + HAART</arm_group_label>
    <other_name>LC002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dextrose/glucose solution</description>
    <arm_group_label>Placebo + HAART</arm_group_label>
    <other_name>LC002 Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>Three or more antiretroviral drugs that can fully suppress HIV RNA</description>
    <arm_group_label>DermaVir + HAART</arm_group_label>
    <arm_group_label>Placebo + HAART</arm_group_label>
    <other_name>Highly active antiretroviral therapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood mononuclear cells (PBMC) and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  HIV-1 infection

          -  On a non-hydroxyurea based HAART for at least one year

          -  Pre-HAART CD4 nadir &gt; 250 cells/mm3

          -  Pre-HAART viral load &gt; 5,000 copies/mL

          -  Undetectable viral load for the six month period preceding the study

          -  CD4 T-cell count &gt;500 cells/mm3 for the six month period preceding the study

        Main exclusion Criteria:

          -  No skin disease

          -  No hypersensitivity to adhesive tape or Tegaderm

          -  No history of keloid

          -  No history of vitiligo, melasma, skin cancer

          -  No tattoos or changes in pigment at the skin treatment sites

          -  No autoimmune diseases

          -  No hepatitis B, C coinfections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Maserati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico S. Matteo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Lori, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ViroStatics srl</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.geneticimmunity.com</url>
    <description>Genetic Immunity's homepage</description>
  </link>
  <link>
    <url>http://www.virostatics.com</url>
    <description>Virostatics srl homepage</description>
  </link>
  <reference>
    <citation>Lisziewicz J, Tőke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine. 2013 Jan;9(1):28-38. doi: 10.1016/j.nano.2012.05.012. Epub 2012 May 30. Review.</citation>
    <PMID>22659241</PMID>
  </reference>
  <reference>
    <citation>Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One. 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9.</citation>
    <PMID>22590502</PMID>
  </reference>
  <reference>
    <citation>Lőrincz O, Tőke ER, Somogyi E, Horkay F, Chandran PL, Douglas JF, Szebeni J, Lisziewicz J. Structure and biological activity of pathogen-like synthetic nanomedicines. Nanomedicine. 2012 May;8(4):497-506. doi: 10.1016/j.nano.2011.07.013. Epub 2011 Aug 10.</citation>
    <PMID>21839051</PMID>
  </reference>
  <reference>
    <citation>Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine. 2011 Jan 17;29(4):744-53. doi: 10.1016/j.vaccine.2010.11.019. Epub 2010 Nov 23.</citation>
    <PMID>21109034</PMID>
  </reference>
  <reference>
    <citation>Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol. 2008 May 1;180(9):5907-15.</citation>
    <PMID>18424710</PMID>
  </reference>
  <reference>
    <citation>Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN, Unangst T, Whitman L, Hudacik L, Bakare N, Whitney S, Restrepo S, Suschak J, Ferrari MG, Chung HK, Kalyanaraman VS, Markham P, Pal R. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology. 2007 Sep 15;366(1):197-211. Epub 2007 May 11.</citation>
    <PMID>17499328</PMID>
  </reference>
  <reference>
    <citation>Calarota SA, Weiner DB, Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine. 2007 Apr 20;25(16):3070-4. Epub 2007 Jan 22.</citation>
    <PMID>17292518</PMID>
  </reference>
  <reference>
    <citation>Lori F, Foli A, Lisziewicz J. Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options. Curr Opin HIV AIDS. 2007 Jan;2(1):14-20. doi: 10.1097/COH.0b013e328011aad6.</citation>
    <PMID>19372860</PMID>
  </reference>
  <reference>
    <citation>Xu JQ, Lori F, Lisziewicz J. CD4+ T cell-mediated presentation of non-infectious HIV-1 virion antigens to HIV-specific CD8+ T cells. Chin Med J (Engl). 2006 Oct 5;119(19):1629-38.</citation>
    <PMID>17042976</PMID>
  </reference>
  <reference>
    <citation>Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol. 2005 Jan;124(1):160-9.</citation>
    <PMID>15654970</PMID>
  </reference>
  <reference>
    <citation>Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F. Control of viral rebound through therapeutic immunization with DermaVir. AIDS. 2005 Jan 3;19(1):35-43.</citation>
    <PMID>15627031</PMID>
  </reference>
  <reference>
    <citation>Lori F, Kelly LM, Lisziewicz J. APC-targeted immunization for the treatment of HIV-1. Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S189-98. Review.</citation>
    <PMID>15285717</PMID>
  </reference>
  <reference>
    <citation>Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. Antivir Ther. 2004 Feb;9(1):123-32.</citation>
    <PMID>15040544</PMID>
  </reference>
  <reference>
    <citation>Lisziewicz J, Bakare N, Lori F. Therapeutic vaccination for future management of HIV/AIDS. Vaccine. 2003 Jan 30;21(7-8):620-3. Review.</citation>
    <PMID>12531329</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>February 7, 2013</last_update_submitted>
  <last_update_submitted_qc>February 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immune Therapy</keyword>
  <keyword>DermaVir</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

